[
    [
        {
            "time": "",
            "original_text": "3亿人民币转让4家药企无人问津，上市药企出售资产成风背后的逻辑是什么？ 资产异常",
            "features": {
                "keywords": [
                    "药企",
                    "资产转让",
                    "无人问津",
                    "出售资产"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3亿人民币转让4家药企无人问津，上市药企出售资产成风背后的逻辑是什么？ 资产异常",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196)：贝伐珠单抗类似药报产 生物药进入收获期",
            "features": {
                "keywords": [
                    "复星医药",
                    "贝伐珠单抗",
                    "类似药",
                    "生物药",
                    "收获期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196)：贝伐珠单抗类似药报产 生物药进入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：“恩沙替尼”上市申报现场核查已完成",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "上市申报",
                    "现场核查"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：“恩沙替尼”上市申报现场核查已完成",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]